Novo Nordisk A/S : to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA

 Liraglutide 3.0 mg for Weight Management in Obese/Overweight Adults with Type

2 Diabetes: Results from the SCALE™ Diabetes 56-Week Randomized, Double- blind, Placebo-controlled Trial (Abstract #97-OR)

 One-year Efficacy and Safety of IDegLira in Patients with Type 2 Diabetes

(Abstract #65-OR)
 Impact of BMI on HbA1c Reduction, Hypoglycaemia Rates and Insulin
Requirements in Response to IDegLira in Patients with Type 2 Diabetes (Abstract
#66-OR)

 IDegLira Efficacy Across the Range of Disease Progression in Type 2 Diabetes

(Abstract #0067-OR)

 Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (Abstract #965-P)

 Efficacy and Safety of Liraglutide versus Placebo as Add-on to Existing Diabetes

Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal
Impairment (Abstract #331-OR)

 Rate Ratios for Nocturnal Confirmed Hypoglycaemia with Insulin Degludec vs.

Insulin Glargine Using Different Definitions (Abstract #402-P)
The above are a sampling of the abstracts that will be presented or published by Novo
Nordisk. A complete listing of abstracts being presented and published at the Scientific
Sessions of the ADA can be accessed here.

Corporate Communications

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet: www.novonordisk.com CVR no:

24 25 67 90

Page 2 of 2

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately

40,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.

Corporate Communications

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet: www.novonordisk.com CVR no:

24 25 67 90

distributed by